Compounded injectable Formula F9 recalled for insufficient potency
Olympia Compounding Pharmacy recalled Formula F9, a compounded injectable medication, because the product was sub-potent with insufficient active ingredient. The recall affected 493 vials distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class III recall for sub-potency, a quality issue affecting product efficacy. This is a voluntary manufacturer-initiated recall, consistent with Class III recalls which are typically scored 1-2. The source text does not report deaths, serious injuries, or illnesses.
Plain-English summary
Olympia Compounding Pharmacy is recalling Formula F9, a multi-dose injectable medication containing Papaverine, Phentolamine, PGE, and Atropine. The recall was initiated on March 8, 2022.
The recall was issued because the product was determined to be sub-potent, meaning it contains insufficient amounts of its active ingredients compared to the labeled specification.
The affected lot (D41C19, expiring April 19, 2022) consisted of 493 vials distributed nationwide in the USA, including Puerto Rico. This was a voluntary recall initiated by the manufacturer.
Patients or healthcare providers who have this medication should consult with their healthcare provider to determine if the medication they received was affected and whether any follow-up is needed. The recall was completed on October 4, 2023.
The recalled product
- Product
- Formula F9, Papaverine 0.9 mg/mL, Phentolamine 0.1 mg/mL, PGE 20 mcg/mL, Atropine 0.01 mg/mL, Multi-Dose 10 mL vial, Each ML contains: 0.5% Chlorobutanol NF, 0.005% Edetate Disodium Dihydrate USP, 2.74% Benzyl Alcohol NF, 5% Mannitol USP, 1% Sodium Metabisulfite NF, 1% Ethyl Alco
- Category
- Drug — Injectable / Compounded
- Hazard
- Affected units
- 493
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: D41C19 Exp. 4/19/22
Distribution
Part of a larger recall action
This product is one of 7 recalled by Olympia Compounding Pharmacy dba Olympia Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 7 products in this recall →Related recalls
Same manufacturer · Olympia Compounding Pharmacy dba Olympia Pharmacy
See all →- HighLidocaine 2% injectable solution recalled for lack of sterility assurance
FDA (Drugs) · 2022-06-01
- HighFDA Recalls Compounded Papaverine Injection Due to Sterility Assurance
FDA (Drugs) · 2022-06-01
- HighFDA Recalls Testosterone Cypionate Injection Vials for Lack of Sterility Assurance
FDA (Drugs) · 2022-06-01
- HighCompounded pharmaceutical vials recalled due to sterility assurance failure
FDA (Drugs) · 2022-06-01
- HighOndansetron Hydrochloride vials recalled due to sterility assurance concerns
FDA (Drugs) · 2022-06-01
Same hazard · sub potent
See all →- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
- HighEquate Hand Sanitizer recalled for potency non-compliance in Puerto Rico
FDA (Drugs) · 2023-11-22
- ModerateOxycodone Tablets Recalled for Lower Potency Than Labeled
FDA (Drugs) · 2023-11-15
- ModerateSermorelin Acetate Injectable Recalled for Sub-Potent Strength
FDA (Drugs) · 2022-03-30
- LowHydroxocobalamin B12 Injection Recalled for Sub-Potent Dose
FDA (Drugs) · 2022-03-30